GlassScriptPhysician profile
Andra Mirela Popescu
NPI 1952519118
$3,433.03
in general payments reported to CMS, 2019-2025
31 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $847 · 2021: $637 · 2022: $381 · 2023: $227 · 2024: $159 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.82 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $457.00 | 2019-2023 | Farxiga |
| Amgen INC. | $437.76 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $250.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $228.72 | 2019-2024 | |
| Pfizer INC. | $221.28 | 2019-2025 | |
| Amarin Pharma, INC. | $211.37 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $166.92 | 2019-2022 | |
| Abbott Laboratories | $111.59 | 2020-2025 | Aveir |
| Bard Peripheral Vascular, INC. | $93.02 | 2019 | |
| Merck Sharp & Dohme LLC | $88.95 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $67.27 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.29 | 2019-2020 | |
| Abbvie INC. | $61.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $58.92 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $41.45 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $36.32 | 2021 | |
| Lilly USA, LLC | $32.83 | 2021-2022 | |
| Corcept Therapeutics | $28.76 | 2024 | Korlym |
| Boston Scientific Corporation | $27.67 | 2019 | |
| Esperion Therapeutics, INC. | $24.72 | 2020 | |
| Philips North America LLC | $19.27 | 2020 | |
| Sunovion Pharmaceuticals INC. | $18.55 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.22 | 2022 | |
| Novo Nordisk INC | $15.20 | 2019 | |
| Medtronic USA, INC. | $15.17 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.95 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.56 | 2021 | |
| Eisai INC. | $12.87 | 2021 | |
| Neos Therapeutics, LP | $12.63 | 2022 | |
| Vistapharm, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andra Popescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.